BIOA advances BGE-102 to two Phase II trials for DME
BIOA said BGE-102 has advanced to two Phase II trials, including DME, with “strong biomarker and safety data.” The oral therapy targets ophthalmology and metabolic disease needs; pivotal data is expected next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.